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A randomised controlled trial of comprehensive early intervention care in patients with 
first-episode psychosis in Japan: 1.5-year outcomes from the J-CAP study  
 
ABSTRACT 
Background: The first episode of psychosis represents a critical period wherein comprehensive 
early intervention may alter the course of illness. However, evidence from randomized controlled 
trials which examined the impact of comprehensive early intervention care is limited. 
Aims: To conduct a multi-centre trial comparing comprehensive early intervention care and 
standard care in young patients with first-episode psychosis (FEP) in Japan. 
Method: Individuals with FEP (ages 15–35 years) were randomised to receive standard care or 
specialized comprehensive care and were followed-up until 1.5 years (trial no.: 
UMIN000005092).  
Results: The specialized care group had a lower treatment dropout rate (odds ratio, 0.038; 95% 
confidence interval, 0.002–0.923) and higher clinical remission rate (odds ratio, 6.3; 95% 
confidence interval, 1.0–37.9) than the standard care group, even after adjusting for baseline 
characteristics.  
Conclusions: Comprehensive early intervention care may provide advantages over standard care 
in Japanese patients with FEP. 





In recent decades, several early intervention services have been established to target young 
individuals with first-episode psychosis (FEP). Early intervention is based on the hypothesis that 
the initial years of psychosis represent a critical period in which comprehensive early intervention 
care can alter the course of the illness. Yet, few randomised controlled trials have assessed the 
effects of comprehensive early intervention care programs in individuals with FEP. The results of 
previous randomised studies conducted in Denmark (OPUS trial1-3), England (LEO trial4, 5) and 
the United States (STEP trials6 and the RAISE trial7, 8) suggest that specialized comprehensive 
care for FEP promotes clinical and functional recovery assessed after 1–2 years of therapy. Only 
one randomised controlled trial examined the effect of a 1-year extension for specialized early 
intervention care in an Asian population of patients with FEP,9, 10 and no study to date has 
compared specialized early care and standard care in a young Asian population of patients with 
FEP. Accordingly, we investigated whether comprehensive early intervention care produces 
better outcomes than standard care in young individuals with FEP in Japan using a multi-centre 
randomised controlled design. We hypothesized that comprehensive early intervention care 
would increase the likelihood of clinical and functional recovery and decrease the treatment 
dropout rate at 1.5-year follow-up. 
 
METHOD 
This study was conducted as a part of the Japanese Comprehensive Approach for First-episode 
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Psychosis (J-CAP) study. The aim of the J-CAP study was to develop, test, and implement 
comprehensive early intervention care approaches for young people with FEP. The background, 
rationale, and design of the J-CAP study have been previously described elsewhere.11 
 
Subjects 
A total of 77 individuals were enrolled in the study (CONSORT diagram shown in Figure 1). 
Candidate participants were patients who received a diagnosis of F2 or F3 with psychotic 
symptoms as per the International Classification of Disease, 10th revision at a participating 
clinical site. The inclusion criteria were: (1) first-episode psychosis; (2) age between 15–35 years; 
(3) onset of franc psychotic symptoms in the previous 5 years; and (4) residence in the catchment 
area of each clinical site. The onset of psychotic symptom was defined as the first clear evidence 
of a psychotic symptom (i.e., delusion, hallucination, or thought disorder) scored 4 or higher on 
the Positive and Negative Symptom Scales (PANSS12). The exclusion criteria were: (1) a 
premorbid intelligence quotient of < 80; (2) inability to sufficiently communicate in Japanese; (3) 
requirement of care for any organic mental disorder or inpatient care for any physical condition; 
(4) history of dependency on alcohol and/or other substances; (5) completion of electroconvulsive 
therapy and/or transcranial magnetic stimulation therapy within the past month; and (5) any 
patient deemed ineligible by the attending physician for any other reason. Although the use of 
substances such as cannabis has become a major issue worldwide, a very small number of young 
people use these drugs in Japan.13 Therefore, we adopted a history of continuous substance 
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dependence as an exclusion criterion in this trial. All patients were assessed for eligibility by 
psychiatrists at each participating site. 
Written informed consent was obtained from all participants and from the legal 
guardians of participants younger than 20 years of age. The study was approved by the 
institutional review boards of the coordinating centre and participating sites (Tokyo Metropolitan 
Institute of Psychiatry, no. H22-23; University of Tokyo, no. 3307; Matsuzawa, no. 22-23; Mie, 
no. H23.2.21; Okayama, no. H24-6; and Hinaga, no. H22.12.22). The J-CAP Safety Monitoring 
Board provided study oversight. 
 
Clinical sites and randomisation 
The study was conducted at 5 clinical mental health sites in 3 cities: The University of Tokyo 
Hospital, Tokyo Metropolitan Matsuzawa Hospital, Mie Prefectural Mental Medical Center, 
Hinaga General Center for Mental Care and Sasagawa Clinic, and Okayama Mental Medical 
Centre. Relevant details for these sites are summarised in Table S1. The site eligibility criteria 
were having an early intervention service for people with FEP and more than 2 clinicians who 
participated in the early intervention training program provided by clinical experts on early 
intervention for psychosis in England (Dr. Jo Smith and Dr. Paul French).  
The J-CAP was designed as an interventional, parallel, single-blinded (open label but 
blinded raters) trial. Participants were randomly assigned to the specialized comprehensive early 
intervention care approach (CAP) group or to a standard care (SC) group. In the CAP group, an 
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early intervention team provided comprehensive community-based care for 18 months. In the SC 
group, participants received standard care for 18 months.  
Assessments of clinical and functional data were conducted upon enrolment and at the 
18-month follow-up. While the target sample size was originally 150,11 we were unable to recruit 
a sufficient number of participants even after the registration period was extended by the study 
committee. The study committee stopped recruitment on September 30, 2014 when we achieved a 
sample size sufficient to evaluate an important secondary outcome (i.e., dropout from 
treatment).14 This trial was registered with the University Hospital Medical Information Network 
Clinical Trials Registry (UMIN-CTR) and accepted by the International Committee of Medical 
Journal Editors (ICMJE) (no. UMIN000005092). 
 
Interventions 
Comprehensive early intervention community-based care was provided over a period of 18 
months after study enrolment by specialized CAP teams consisting of trained case managers and 
psychiatrists. CAP teams followed the clinical guideline and practice manual for promoting 
recovery from early psychosis15, 16 and tailored interventions with established efficacy to meet the 
needs of young patients and their families. Case managers sought to promote patient clinical and 
functional recovery using a combination of cognitive-behavioural psychotherapy, family 
education and support, support for vocational and educational recovery, and relapse prevention 
strategies. Psychiatrists in the CAP group discussed about pharmacological therapy with case 
6 
 
managers and prescribed medicines in accordance with the clinical manual for FEP.15, 16 The care 
components of the CAP have been previously described elsewhere11. To standardize the intensity 
and quality of comprehensive early intervention care, CAP teams participated in follow-up 
training courses and supervision meetings at least twice per year. Supervisors in the CAP 
coordinating centre (Tokyo Metropolitan Institute of Medical Sciences) who provided 
supervision for the CAP teams at each clinical site were trained and supervised by clinical experts 
on early intervention for psychosis in England (Dr. Jo Smith and Dr. Paul French). 
Standard care (SC) or “community care as usual” included psychosis treatment as 
prescribed by a clinician choice and service availability. Clinicians who provided standard care 
received no additional training or supervision except for guidance regarding subject recruitment.  
 
Assessments 
We adopted the function domain score of the global assessment of functioning (GAF-F)17 as a 
primary outcome measure. Other outcome measures were dropout rate, remission rate based on 
Positive and Negative Syndrome Scale (PANSS) scores,18 PANSS total score, World Health 
Organization Quality of Life 26-item version (WHO-QOL 2619, 20) score, educational and 
vocational recovery rates, and care satisfaction of participants and families. The GAF-F, dropout 
rate, remission rate, and PANSS were evaluated by blinded raters and other measurements were 





The Global Assessment of Functioning (GAF21) records the current objective symptomatic and 
functional statuses of participants on an analogue scale ranging from 0 (poor) to 100 (good). We 
used the modified GAF scale17 to assess functional and symptomatic statuses separately and to 
calculate GAF-F and GAF-S scores. The GAF-F rates social and occupational function and the 




Dropout rate was defined on follow-up point as the refusal of further treatment despite a need for 
treatment and several attempts at reengagement (phone calls to patients in both groups and home 
visits to participants in the CAP group).  
 
Remission rate 
Remission rate was defined using a proposal from the Remission in Schizophrenia Working 
Group18 that defined symptomatic remission of illness as mild or less on all items of 8 PANSS 
subscores (P1, P2, P3, N1, N4, N6, G5, and G9), maintained for at least 6 months. 
 
PANSS 
The PANSS evaluates the current objective symptoms of patients using 30 items in 3 domains: 
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positive symptoms, negative symptoms, and general psychopathology.12 Each item is rated from 1 
(absent) to 7 (extreme), and the total score ranges from 30 to 210. 
 
WHO-QOL 26 
The WHO-QOL 26 assesses the current subjective satisfaction of participants with their quality of 
life using 26 items in 4 domains: physical health, psychological health, social relationships, and 
environment.19,20 Each item is rated from 1 (poor) to 5 (good), and the total score is calculated as 
the average of all subscores. 
 
Occupational/educational recovery rate 
Occupational/educational recovery was assessed using the definition sheet from the UK National 
EDEN study23. We used the “training and occupation” section, which is rated from 0 
(employment) to 4 (not in education, employment or training), to assess participant’s recovery 
status. We rated scores based on each participant’s best occupational/educational status achieved 
within the last 6 months at baseline and follow-up. 
 
Care satisfaction 
Care satisfaction was evaluated using a single item rated from 1 (very satisfied) to 4 (very 






We analysed the data on an intention-to-treat basis. To examine effects of the intervention, we 
used t-tests to compare mean differences and confidence intervals for continuous variables 
between groups. Multilevel linear and multilevel logistic regressions were used to examine 
effects of the intervention while adjusting for baseline characteristics. Because data were taken 
from multiple patients from each clinical site, multilevel modelling was used for multivariate 
analyses. The model included random effect for each clinical site to account for within-site 
correlations. All statistical analyses were conducted using Stata MP for Windows, version 14.0 
(StataCorp, College Station, Texas, USA). The two-tailed significance level was set at 0.05. 
 
Results 
Baseline characteristics of the study participants are shown in Table 1. A total of 77 participants 
were enrolled; of these, 40 were randomised to the CAP group and 37 to the SC group. 
Participants were predominantly living with their families (87%) and 51% were male. The mean 
age at baseline was 23.0 years (standard deviation = 5.1 years) and the mean duration of untreated 
psychosis was 16.8 months (standard deviation = 14.1 months; median = 12.7 months). 
Seventy-five participants were diagnosed as F2 and 2 participants were diagnosed as F3. There 
were no significant between-group differences in baseline clinical or functional characteristics 
except for symptom severity (PANSS total score: P = 0.003).  
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GAF-F scores in the CAP group at the 18-month follow-up were slightly higher than 
those in the SC group, but this difference was not statistically significant before (P = 0.195) or 
after adjusting for baseline variables (P = 0.332) (Table 2); however, the CAP group had a 
significantly lower dropout rate (2.5% vs. 21.6%; odds ratio [OR] = 0.038, 95% confidence 
interval [CI] = 0.002–0.923, P = 0.045) and significantly higher remission rate (OR = 6.29, 95% 
CI = 1.04, 95%on P = 0.045) than the SC group, even after adjusting for baseline variables. 
Family member care satisfaction was also significantly higher in the CAP group than in the SC 
group (OR = 3.69, 95% CI = 1.05–13.00, P = 0.042), but this difference did not remain significant 
after adjusting for baseline characteristics (P = 0.697). No significant group differences were 




In the present study, we found that young patients with FEP who received specialized 
comprehensive early intervention care had a decreased risk of dropout and increased clinical 
remission, as compared with those who received standard care; however, we did not identify 
significant between-group differences in functional outcomes. Dropout from mental health 
services is an important issue for young people with FEP,24 especially given that outcome 
trajectories are established relatively early, usually during the first 2–5 years after illness onset.25 
A recent meta-analysis reported that specialized early intervention care for individuals with FEP 
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reduced the risk of dropout from treatment,26 although dropout rates remain high (20.5–40%) 
even in the context of these specialized programs.24 Compared with these previous studies, the 
dropout rate in our CAP group was quite low (2.5%); this may have been due to our sampling 
criteria, as we excluded individuals with comorbid substance use disorders, which have been 
identified as risk factors for service disengagement in other countries.24 Statistically robust 
improvements in the clinical remission rate in our CAP group are consistent with the findings of a 
previous study where specialized care was provided for early psychosis.27 Current 
multicomponent treatment programs for FEP emphasize a combination of psychosocial and 
pharmacological interventions as the first line treatment,28, 29 and evidence suggests that this 
combined treatment approach promotes clinical remission among individuals with FEP compared 
to medication alone.30, 31 To this end, we noted that lower doses of antipsychotics were prescribed 
to patients in our CAP group compared to the SC group. International treatment guidelines for 
FEP recommend the use of low-dose antipsychotic medication,15 as high or excessive medication 
can increase the risk of physical health deterioration and poor functional recovery in young 
patients with FEP.32 Taken together, these findings suggest that comprehensive early intervention 
care can reduce the risk of high or excessive antipsychotic medication use and associated adverse 
outcomes. 
To the best of our knowledge, this is the first randomised controlled trial to examine 
effects of comprehensive early intervention care in an Asian cohort of young individuals with FEP. 
While we provide evidence that comprehensive early intervention care reduces treatment dropout 
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and promotes clinical remission, several important study limitations should be considered. First, 
our sample size was not large enough to detect changes in the primary outcome measure. As a 
result, the statistical power of our trial was limited. Second, the follow-up duration in our study 
was shorter than those in similar previous studies.3, 5 The OPUS trial in Denmark reported that the 
benefits of specialized early intervention care in patients with FEP were most notable after 2 and 5 
years of treatment, whereas positive effects were diminished at 10-year follow-up,3 and a similar 
pattern was seen in the LEO trial in the UK that used a 5-year follow-up period.5 Accordingly, a 
longer follow-up period may be required to investigate the sustainable efficiency of CAP 
treatment in future studies. Third, there were no physical health outcomes in our J-CAP study. 
Psychotic disorders are associated with a 10–30-year gap in life expectancy relative to the general 
population33, 34 and premature mortality has been related to higher incidences of cardiovascular 
disease and obesity-related cancers in these patients.35 Recent studies have shown a high 
prevalence of cardiometabolic risk factors among young people with first-episode schizophrenia 
spectrum disorders.36 Future studies should include physical health-related outcomes as important 
targets of early intervention programs for young people with FEP.37 
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